Takeda Pharmaceutical Co (NYSE: TAK) — Company Overview, News & Financial Data
Takeda Pharmaceutical (TSE:4502), (NYSE:TAK) is a global biopharmaceutical company focused on bringing forward innovative medicines and treatments to
Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a global, research-based biopharmaceutical company headquartered in Tokyo, Japan. The enterprise focuses on researching, developing, manufacturing, and commercializing prescription medicines across key therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Operating in approximately 80 countries and territories across North America, Europe, Asia-Pacific, and Latin America, the organization maintains manufacturing facilities, research laboratories, and plasma donation centers worldwide. Its operations encompass clinical development, global supply chain management, and commercial distribution to deliver specialized treatments and therapies to healthcare providers and patients globally.
Snapshot
Operations
Products and/or services of Takeda Pharmaceutical Co
- Gastroenterology Therapies: Development and commercialization of treatments for inflammatory bowel disease, acid-related disorders, short bowel syndrome, and eosinophilic esophagitis. Core products include biologic therapies and targeted oral medications supplied to global clinical networks and pharmacy channels.
- Plasma-Derived Therapies: Collection of human plasma through dedicated donation centers and production of plasma-derived immunoglobulins, albumin, and specialty biotherapies. Operations involve large-scale fractionation facilities supplying hospitals and specialized clinical facilities across major international markets.
- Rare Disease Treatments: Formulation and distribution of targeted therapies for rare metabolic, genetic, and hematologic disorders, including hereditary angioedema and lysosomal storage disorders. Products are delivered directly to specialized medical centers and patients across worldwide regions.
- Oncology Medicines: Research, manufacture, and global distribution of specialized targeted therapies and small molecule inhibitors for blood cancers and solid tumors. Clinical operations provide treatments for multiple myeloma, lung cancer, and colorectal cancer to medical oncology centers globally.
- Neuroscience Pharmaceuticals: Development and supply of prescription pharmaceutical treatments for central nervous system conditions, including attention-deficit/hyperactivity disorder, major depressive disorder, narcolepsy, and sleep disorders, distributed through national health systems and prescription fulfillment networks.
- Vaccine Products: Manufacturing and international distribution of preventative vaccines targeting infectious diseases, including live-attenuated dengue vaccines. Facilities supply government health authorities, public immunization programs, and global health initiatives across endemic regions and overseas health agency channels.
Takeda Pharmaceutical Co executive team
- Mr. Christophe WeberPresident, CEO & Representative Director
- Mr. Milano FurutaCFO & Director
- Dr. Andrew S. Plump M.D., Ph.D.President of Research & Development and Representative Director
- Dr. Seigo IzumoChair of Management Board
- Mr. Haruhiko HirateMember of Management Board
- Mr. Salvatore Alesci M.D., Ph.D.Member of Management Board and Head of R&D Global Science & Biomedical Policy
- Norimasa TakedaChief Accounting Officer & Corporate Controller
- Mr. Iwaaki TaniguchiSenior Vice President of Corporate Finance & Controlling Department
- Mr. Gabriele RicciChief Data & Technology Officer
- Mr. Christopher David O'ReillyGlobal Head of Investor Relations & Global Finance